Memantine ER/Donepezil: A Review in Alzheimer’s Disease
- 1.1k Downloads
A once-daily, fixed-dose combination of memantine extended-release (ER)/donepezil 28/10 mg (Namzaric™) is available in the USA for patients with moderate to severe Alzheimer’s disease (AD) on stable memantine and donepezil therapy. The fixed-dose formulation is bioequivalent to coadministration of the individual drugs. In a 24-week, phase III trial in patients with moderate to severe AD, addition of memantine ER 28 mg once daily to stable cholinesterase inhibitor (ChEI) therapy was more effective than add-on placebo on measures of cognition, global clinical status, dementia behaviour and semantic processing ability, although between-group differences on a measure of daily function did not significantly differ. In subgroup analyses in donepezil-treated patients, add-on memantine ER was more effective than add-on placebo on measures of cognition, dementia behaviour and semantic processing, although there were no significant between-group differences on measures of global clinical status and daily function. Memantine ER plus ChEI combination therapy was generally well tolerated in the phase III trial, with diarrhoea, dizziness and influenza occurring at least twice as often with add-on memantine ER as add-on placebo in donepezil-treated patients. Thus, memantine ER plus donepezil combination therapy is an effective and well tolerated treatment option for patients with moderate to severe AD. The fixed-dose combination is potentially more convenient than coadministration of the individual agents.
KeywordsMemantine Rivastigmine Verbal Fluency Test Severe Impairment Battery Coprimary Endpoint
During the peer review process, the manufacturer of memantine ER/donepezil was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflict of interest
Sarah Greig is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
- 5.Hendrix S, Ellison N, Stanworth S, et al. Post hoc evidence for an additive effect of memantine and donepezil: consistent findings from DOMINO-AD study and memantine clinical trial program. J Prev Alzheimers Dis. 2015;2(3):165–71.Google Scholar
- 7.Atri A, Molinuevo JL, Lemming O, et al. Memantine in patients with Alzheimer’s disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimers Res Ther. 2013;5(1):[article no. 6].Google Scholar
- 11.Forest Pharmaceuticals Inc. Namzaric™ (memantine hydrochloride extended-release and donepezil hydrochloride) capsules, for oral use: US prescribing information. 2014. http://www.fda.gov. Accessed 14 Oct 2015.
- 14.Boinpally R, Chen L, Zukin SR, et al. A novel once-daily fixed-dose combination of memantine extended release and donepezil for the treatment of moderate to severe Alzheimer’s disease: two phase I studies in healthy volunteers. Clin Drug Investig. 2015;35(7):427–35.PubMedCentralCrossRefPubMedGoogle Scholar
- 15.Grossberg GT, Manes F, Allegri RF, et al. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer’s disease taking cholinesterase inhibitors. CNS Drugs. 2013;27(6):469–78.PubMedCentralCrossRefPubMedGoogle Scholar
- 16.Grossberg GT, Alva G, Hendrix S, et al. Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer’s disease: subset analysis of a randomized clinical trial [abstract no. P1-370 plus poster]. Alzheimers Dement. 2014;10(4 Suppl):P450.CrossRefGoogle Scholar
- 17.Atri A, Hendrix SB, Pejovic V, et al. Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis. Alzheimers Res Ther. 2015;7(1):[article no. 28].Google Scholar
- 18.Hendrix S, Ellison N, Otcheretko V. Complementary benefit of memantine and donepezil on activities of daily living by disease stage when used together: post hoc analysis of two trials in moderate to severe Alzheimer’s disease [abstract no. 2710 plus poster]. In: Alzheimer’s Association International Conference. 2015.Google Scholar
- 19.Atri A, Hendrix S, Ellison N, et al. Caregiver distress related to neuropsychiatric symptoms is reduced with extended-release memantine-cholinesterase inhibitor combination in patients with moderate to severe Alzheimer’s disease [abstract no. 4636 plus poster]. In: Alzheimer’s Association International Conference. 2015.Google Scholar
- 21.Rountree SD, Chan W, Pavlik VN, et al. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res Ther. 2009;1(2):[article no. 7].Google Scholar
- 24.Saint-Laurent Thibault C, Stillman IO, Chen S, et al. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer’s type in the United States. J Med Econ. 2015. doi: 10.3111/13696998.2015.1063501.